| ID: | 178 | |
|---|---|---|
| Name: | Compound 178 | |
| Description: | Original numeration in publication: 18 | |
| Labels: | Training_set, Thiazolidine-2, 4-dione | |
| CAS: | ||
| InChi Code: | InChI=1S/C27H19Cl2N3O6S/c1-38-26(36)16-5-10-20(11-6-16)31-24(34)15-3-8-19(9-4-15)30-23(33)14-32-25(35)22(39-27(32)37)12-17-2-7-18(28)13-21(17)29/h2-13H,14H2,1H3,(H,30,33)(H,31,34)/b22-12- |
pIC50: Negative logarithm of half-maximal inhibitory concentration [-log(uM)]
| Value | Source or prediction |
|---|---|
| 6.77 |
El-Adl, K.; El-Helby, A.-G. A.; Sakr, H. a. A., R. R.; Mahdy, H. A.; Nasser, M. a. A., H. S.; El-Hddad, S. S. A. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Arch. Pharm. (Weinheim) 2021, 354, e2000279. https://doi.org/10.1002/ardp.202000279 |
| 6.37789 |
Eq1: VEGFR-2 inhibition (Data used to train model) |